| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $254K | — |
| SG&A Expense | $16.9M | — |
| Operating Income | -$17.1M | — |
| Pre-tax Income | -$43.2M | — |
| Income Tax | -$15.7M | — |
| Net Income | -$27.5M | — |
| EPS (Diluted) | -$0.07 | — |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $4.1M | +297.2% |
| Current Assets | $6.8M | +558.1% |
| Total Assets | $93.7M | +5953.3% |
| Current Liabilities | $3.7M | -29.3% |
| Total Liabilities | $12.1M | +122.2% |
| Stockholders' Equity | $81.5M | +2182.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$4.6M | — |
| Capital Expenditures | $0 | — |
| Investing Cash Flow | $0 | — |
| Financing Cash Flow | -$99K | — |
| Free Cash Flow | -$4.6M | — |